Table 2.

Cell cycle distribution analysis in i.p. tumor xenografts of LS-174T following treatment with ²¹²Pb-TCMC-trastuzumab.

Treatment	Phase	Time point (h)
		0	6	24	48	72	96	120
	G1	67.5±2.7
	S	17.7±2.0
	G2-M	14.8±0.7
212Pb-Trastuzumab	G1		68.6±3.8	66.9±1.3	67.7±4.0	68.1±1.3	66.6±0.7	73.2±0.1
	S		14.3±5.4	5.9±0.1	6.3±1.8	7.9±0.7	3.6±0	4.6±1.9
	G2-M		17.1±1.6	27.3±1.2	26.1±2.1	23.9±0.6	29.7±0.7	22.2±2.0
212Pb-HuIgG	G1		63.9±5.2	65.1±2.3	64.6±	67.1±0.5	63.1±0.3	65.5±2.6
	S		20.0±5.3	7.4±1.3	5.8±	5.5±0.1	7.8±0.7	17.1±3.6
	G2-M		16.0±0.1	27.5±1.0	29.6±	27.4±0.6	29.1±1.0	17.5±0.9
Trastuzumab	G1		69.5±2.6	63.3±1.6	68.0±0.1	61.3±1.8	65.1±3.3	73.3±4.3
	S		21.7±3.4	26.0±3.2	22.0±1.8	28.1±1.6	23.5±4.3	14.8±2.9
	G2-M		8.9±0.9	10.7±1.6	10.1±1.7	10.7±3.4	11.5±1.0	11.9±1.4
HuIgG	G1		72.3±3.4	70.3±3.4	70.6±2.3	60.6±1.6	73.9±1.0	74.6±2.2
	S		22.0±3.4	19.8±2.1	20.9±1.9	26.6±1.8	19.6±2.2	18.2±2.3
	G2-M		5.7±0	9.8±1.4	8.4±0.4	12.8±0.2	6.6±1.2	7.2±4.5

Results represent the average of a minimum of three replications (± SD).